Matinas BioPharma inks new chief development officer

By ROI-NJ Staff
Bedminster | Oct 16, 2018 at 7:15 am

Matinas BioPharma Holdings Inc., a biopharmaceutical company, announced it has appointed Theresa Matkovits as its new chief development officer.

The Bedminster-based company also announced it has hired Frank Calamusa as executive director, head of manufacturing and supply chain, and Jenel Cobb as director, project management, to strengthen its manufacturing, supply chain and clinical development teams.

“We are thrilled to have Theresa and her team join Matinas at such an important inflection point for our Company,” Jerome Jabbour, CEO of Matinas, said. “Dr. Matkovits is a well-known and respected pharma and biotech leader and her in-depth knowledge of the industry and the key relationships she has established over the course of her career in the pharma sector will be invaluable.”

Matkovits has extensive experience in drug development and commercialization in the C-level.

“This is a very exciting time for the Matinas team. The company has generated compelling data and demonstrated its LNC platform to be a potential best-in-class delivery system for the safe, targeted intracellular delivery of a broad range of molecules,” Matkovits said. “I am looking forward to working with the team to capitalize on the potentially significant opportunities within our reach.”

ROI-NJ Staff | editorial@roi-nj.com | @ROINJNews